NBIX Neurocrine Biosciences Inc.

80.83
-3.67  -4%
Previous Close 84.5
Open 83.75
Price To Book 18.04
Market Cap 7,378,721,986
Shares 91,286,923
Volume 949,297
Short Ratio
Av. Daily Volume 904,011

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation 2Q/3Q 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - children
Pivotal trial to be initiated 2H 2019 pending talks with FDA.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
INGREZZA
Tardive dyskinesia
NDA filing planned for 2Q 2019.
Opicapone
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
NDA filing due mid-2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 data due late-2019.
INGREZZA - T-Force PLATINUM
Tourette syndrome - pediatric

Latest News

  1. See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
  2. Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
  3. Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
  4. Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
  5. Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT
  6. Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount?
  7. Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
  8. Not Ready to Rally
  9. AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
  10. Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
  11. Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
  12. Trade Anxieties Return with a Vengeance
  13. Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
  14. Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
  15. Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
  16. Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
  17. Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
  18. Neurocrine Biosciences Has Robust Late-Stage Pipeline